Confident LC-MS Identification of Low ppm Host Cell Proteins (HCPs) in Biotherapeutic Monoclonal Antibodies
Posters | 2020 | Thermo Fisher Scientific | ASMSInstrumentation
Host cell proteins (HCPs) represent critical quality attributes in monoclonal antibody (mAb) therapeutics, as residual impurities can affect safety and efficacy. Detecting HCPs at low parts-per-million (ppm) levels is challenging due to the large dynamic range between the drug product and trace impurities. A sensitive and robust liquid chromatography–mass spectrometry (LC-MS) workflow that reduces the dominance of the mAb and improves HCP detection is therefore of high practical and regulatory importance.
This study aims to develop and validate a workflow for confident identification and label-free quantification of low-abundance HCPs in a reference monoclonal antibody (NISTmAb). The main goals are to:
Sample Preparation and Digestion:
Chromatography and Mass Spectrometry:
Data Processing:
The optimized non-denaturing digest significantly reduced mAb proteolysis, narrowing sample dynamic range and enhancing HCP detectability. Across triplicate analyses, over 100 HCPs were confidently identified at levels from 222 ppm down to below 0.5 ppm, each with at least two peptides in two replicates. High mass accuracy (<2 ppm) and high-quality MS2 spectra supported unambiguous identifications. Label-free quantification yielded measured ppm values consistent with literature reports, demonstrating both sensitivity and reproducibility.
This workflow offers:
Emerging directions include integrating ion mobility separations to further resolve co-eluting peptides, employing faster acquisition modes for increased throughput, and applying machine-learning algorithms to improve deconvolution of complex spectra. Such enhancements will enable deeper coverage of HCP profiles, real-time process monitoring, and broader adoption in biopharmaceutical quality control.
The presented non-denaturing LC-MS workflow combining SMART Digest at reduced temperature, high-performance UHPLC, Orbitrap Exploris 480 detection, and advanced data processing reliably identifies and quantifies HCPs at sub-ppm levels. This approach strengthens biotherapeutic characterization and supports regulatory compliance.
LC/HRMS, LC/MS, LC/MS/MS, LC/Orbitrap
IndustriesPharma & Biopharma
ManufacturerThermo Fisher Scientific
Summary
Significance of the Topic
Host cell proteins (HCPs) represent critical quality attributes in monoclonal antibody (mAb) therapeutics, as residual impurities can affect safety and efficacy. Detecting HCPs at low parts-per-million (ppm) levels is challenging due to the large dynamic range between the drug product and trace impurities. A sensitive and robust liquid chromatography–mass spectrometry (LC-MS) workflow that reduces the dominance of the mAb and improves HCP detection is therefore of high practical and regulatory importance.
Objectives and Study Overview
This study aims to develop and validate a workflow for confident identification and label-free quantification of low-abundance HCPs in a reference monoclonal antibody (NISTmAb). The main goals are to:
- Minimize mAb proteolysis to reduce sample dynamic range.
- Enhance chromatographic and mass spectrometric performance for trace HCP detection.
- Apply advanced data processing to ensure high-confidence protein identifications.
Methodology and Instrumentation
Sample Preparation and Digestion:
- NISTmAb (RM 8671) was concentrated to 80 µg/µL and spiked with known reference proteins for quantification.
- Non-denaturing tryptic digestion was performed using SMART Digest magnetic trypsin beads at 37 °C for 3 h on an automated platform, limiting mAb cleavage.
- Post-digest cleanup involved heat precipitation of undigested protein and reduction with TCEP.
Chromatography and Mass Spectrometry:
- Peptides were separated on a Vanquish Horizon UHPLC system with an Acclaim Vanquish C18 column (2.1×250 mm, 2.2 µm) at 60 °C, 0.3 mL/min flow, over a 90 min gradient of 0.1% formic acid in water to acetonitrile.
- Data-dependent acquisition (Top15) was performed on an Orbitrap Exploris 480 with 120 000 resolution at MS1 and 30 000 at MS2, using a 4 m/z isolation window.
Data Processing:
- Proteome Discoverer 2.4, with the Precursor Detector node, processed chimeric MS2 spectra.
- SEQUEST-HT searched against a UniProt Mus musculus database plus NISTmAb sequences, using 5 ppm precursor and 0.02 Da fragment tolerances.
- Protein identifications required at least two peptides and detection in two of three replicates; label-free quantification used the Precursor Ions Quantifier node.
Main Results and Discussion
The optimized non-denaturing digest significantly reduced mAb proteolysis, narrowing sample dynamic range and enhancing HCP detectability. Across triplicate analyses, over 100 HCPs were confidently identified at levels from 222 ppm down to below 0.5 ppm, each with at least two peptides in two replicates. High mass accuracy (<2 ppm) and high-quality MS2 spectra supported unambiguous identifications. Label-free quantification yielded measured ppm values consistent with literature reports, demonstrating both sensitivity and reproducibility.
Benefits and Practical Applications
This workflow offers:
- Enhanced sensitivity for low-abundance HCPs using analytical-flow UHPLC and HRAM-MS.
- Reduced sample complexity by limiting mAb digestion under non-denaturing conditions.
- High confidence in identifications via advanced data processing of chimeric spectra.
- Quantitative accuracy through spiked reference proteins and label-free methods.
Future Trends and Potential Applications
Emerging directions include integrating ion mobility separations to further resolve co-eluting peptides, employing faster acquisition modes for increased throughput, and applying machine-learning algorithms to improve deconvolution of complex spectra. Such enhancements will enable deeper coverage of HCP profiles, real-time process monitoring, and broader adoption in biopharmaceutical quality control.
Conclusion
The presented non-denaturing LC-MS workflow combining SMART Digest at reduced temperature, high-performance UHPLC, Orbitrap Exploris 480 detection, and advanced data processing reliably identifies and quantifies HCPs at sub-ppm levels. This approach strengthens biotherapeutic characterization and supports regulatory compliance.
Used Instrumentation
- Thermo Scientific Vanquish Horizon UHPLC system with Acclaim Vanquish C18 column.
- Thermo Scientific Orbitrap Exploris 480 mass spectrometer.
- Thermo Scientific SMART Digest magnetic trypsin beads and automated purification.
- Thermo Scientific Bond-Breaker TCEP reduction reagent.
References
- Huang et al. A Novel Sample Preparation for Shotgun Proteomics Characterization of HCPs in Antibodies. Anal. Chem. 2017, 89(10), 5436–5444.
- Doneanu et al. Enhanced Detection of Low-Abundance Host Cell Protein Impurities in High-Purity Monoclonal Antibodies Down to 1 ppm Using Ion Mobility Mass Spectrometry Coupled with Multidimensional Liquid Chromatography. Anal. Chem. 2015, 87(20), 10283–10291.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Residual host cell protein analysis of NISTmAb: From simplified sample preparation to reliable results
2020|Thermo Fisher Scientific|Applications
APPLICATION NOTE 73412 Residual host cell protein analysis of NISTmAb: From simplified sample preparation to reliable results Authors: Amy Claydon, Phil Widdowson, and Andrew Williamson Thermo Fisher Scientific, Hemel Hempstead, UK Keywords: Host cell protein assay, HCP, monoclonal antibody, mAb,…
Key words
denaturing, denaturingdigest, digestnistmab, nistmabhcp, hcpprotein, proteinhcps, hcpsdigestion, digestionsmart, smartnon, nonpeptides, peptidesmab, mabintrasample, intrasamplehost, hostdynamic, dynamickingfisher
Increasing sensitivity of high throughput host cell protein analysis on a novel high- resolution accurate mass platform
2023|Thermo Fisher Scientific|Posters
Increasing sensitivity of high throughput host cell protein analysis on a novel highresolution accurate mass platform Eugen Damoc1; Tabiwang N. Arrey1; Anna Pashkova1; Eduard Denisov1; Kai Scheffler2; Kristina Srzentić3 1Thermo Fisher Scientific (Bremen) GmbH, Bremen, Germany; 2Thermo Fisher Scientific, Germering,…
Key words
hcp, hcphcps, hcpspeptides, peptidespsms, psmsisomerase, isomerasepeptidyl, peptidylper, perprolyl, prolyldenaturing, denaturingprotein, proteinmab, mabdia, dianistmab, nistmabbisphosphate, bisphosphatealdolase
Protein solutions eBook
2024|Thermo Fisher Scientific|Guides
Biopharma Protein solutions eBook Protein therapeutics: At a glance Protein therapeutics are a type of biotherapeutics derived from genetically engineered human proteins. They offer several advantages over small-molecule drugs, allowing for more precise targeting of complex functions. Compared to chemical…
Key words
thermo, thermoscientific, scientificprotein, proteinvanquish, vanquishorbitrap, orbitrapanalysis, analysisintact, intactuhplc, uhplcduo, duobiopharma, biopharmacharacterization, characterizationpeptide, peptideattribute, attributemapping, mappingsubunit
High-sensitivity Host Cell Protein (HCP) analysis on a new Orbitrap Excedion Pro BioPharma hybrid mass spectrometer with optimized sample preparation
2025|Thermo Fisher Scientific|Posters
High-sensitivity Host Cell Protein (HCP) analysis on a new Orbitrap Excedion Pro BioPharma hybrid mass spectrometer with optimized sample preparation Xiaoxi Zhang1, Reiko Kiyonami2, Jae Choi3, Bhavin Patel3, Cong Wang4, Peter Krueger4, Heiner Koch4, Min Du2. 1 Thermo Fisher Scientific,…
Key words
protein, proteinexcedion, excedionhcp, hcphcps, hcpsdepleted, depletedeasypep, easypepdigestion, digestionbiopharma, biopharmaorbitrap, orbitrapnative, nativeagc, agcpro, prodisulfideisomerase, disulfideisomerasephosphopyruvate, phosphopyruvatecalreticulin